CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 390 enrolled
Drug / intervention
CVisc50 OVD +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04192630
NCT04192630N/ACompleted
CompareCT.gov

A Study to Document the Safety and Effectiveness of a New Cohesive OVD When Compared to a Control OVD

Bausch & Lomb Incorporated·interventional·Posted Dec 10, 2019·Updated May 28, 2024

In Brief

A clinical study evaluating CVisc50 OVD, ProVisc OVD, and 1 other intervention for Cataract. Completed, enrolled 390 participants across 22 sites.

Detailed Summary

The objective of the study is to evaluate the safety and effectiveness of the Bausch \& Lomb CVisc50 cohesive OVD compared to the Alcon ProVisc® cohesive OVD when used in cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 10, 2019
Enrollment StartNov 26, 2019
Primary CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.6 years ago

Interventions

CVisc50 OVDdevice

Bausch + Lomb CVisc50 Cohesive OVD

ProVisc OVDdevice

ProVisc OVD

Cataract Surgeryprocedure

Cataract Surgery